(adding content) |
Richardpruen (talk | contribs) (→Suggested additions to this page: Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?) |
||
| Line 1: | Line 1: | ||
<!--T:1--> | <!--T:1--> | ||
<br> | <br> | ||
| Line 1,313: | Line 1,312: | ||
<br> | <br> | ||
='''Suggested additions to this page'''= | ='''Suggested additions to this page'''= | ||
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36650574/ Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?] === | |||
* Nicotine COVID/SARS-CoV-2 interaction mystery takes another turn. | |||
* Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially. This explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, characterizing post-COVID-19 syndrome. The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh). | |||
* We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days. | |||
* Citation: Leitzke M. Bioelectron Med. 2023 Jan 18;9(1):2. doi: 10.1186/s42234-023-00104-7. PMID: 36650574 Free PMC article. | |||
===2022: [https://assets.researchsquare.com/files/rs-1062121/v1/fb8f5195-4cce-470f-9e09-e752fae3c931.pdf?c=1642705044 Part One: Abuse Liability of Vuse Solo Relative To Combustible Cigarettes And Nicotine Gum]=== | ===2022: [https://assets.researchsquare.com/files/rs-1062121/v1/fb8f5195-4cce-470f-9e09-e752fae3c931.pdf?c=1642705044 Part One: Abuse Liability of Vuse Solo Relative To Combustible Cigarettes And Nicotine Gum]=== | ||
===2014: [https://link.springer.com/chapter/10.1007/978-1-4939-1167-7_20 Nicotinic Receptors and Mental Illness]=== | ===2014: [https://link.springer.com/chapter/10.1007/978-1-4939-1167-7_20 Nicotinic Receptors and Mental Illness]=== | ||
===2021: [https://pubmed.ncbi.nlm.nih.gov/34757527/ Meta-Analysis on Nicotine's Modulation of HIV-Associated Dementia]=== | ===2021: [https://pubmed.ncbi.nlm.nih.gov/34757527/ Meta-Analysis on Nicotine's Modulation of HIV-Associated Dementia]=== | ||
===2012: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286320/ Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats]=== | |||
*Animal | *Animal | ||
===2021: [https://www.sciencedirect.com/science/article/abs/pii/S1001841721007804 Real-time effects of nicotine exposure and withdrawal on neurotransmitter metabolism of hippocampal neuronal cells by microfluidic chip-coupled LC-MS]=== | ===2021: [https://www.sciencedirect.com/science/article/abs/pii/S1001841721007804 Real-time effects of nicotine exposure and withdrawal on neurotransmitter metabolism of hippocampal neuronal cells by microfluidic chip-coupled LC-MS]=== | ||
*mouse study | *mouse study | ||
===2021: [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006219.pub4/full Interventions for preventing weight gain after smoking cessation]=== | ===2021: [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006219.pub4/full Interventions for preventing weight gain after smoking cessation]=== | ||
*There was moderate‐certainty that NRT reduced weight at end of treatment and moderate‐certainty that the effect may be similar at 12 months, although the estimates are too imprecise to assess long‐term benefit. | *There was moderate‐certainty that NRT reduced weight at end of treatment and moderate‐certainty that the effect may be similar at 12 months, although the estimates are too imprecise to assess long‐term benefit. | ||
===2004: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]=== | ===2004: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]=== | ||
===2021: [https://link.springer.com/article/10.1007/s12640-021-00375-5 Novel Pharmacotherapies in Parkinson’s Disease]=== | ===2021: [https://link.springer.com/article/10.1007/s12640-021-00375-5 Novel Pharmacotherapies in Parkinson’s Disease]=== | ||
===2021: [[Special:MyLanguage/Nicotine gum enhances visual processing in healthy nonsmokers|Nicotine gum enhances visual processing in healthy nonsmokers]]=== | ===2021: [[Special:MyLanguage/Nicotine gum enhances visual processing in healthy nonsmokers|Nicotine gum enhances visual processing in healthy nonsmokers]]=== | ||
===[https://www.researchgate.net/publication/325159226_Resolution_of_chronic_rhinitis_to_staphylococcus_aureus_in_a_non-smoker_who_started_to_use_glycerine_based_e-cigarettes_Antibacterial_effects_of_vaping Resolution of chronic rhinitis to staphylococcus aureus in a non-smoker who started to use glycerine based e-cigarettes: Antibacterial effects of vaping?]=== | ===[https://www.researchgate.net/publication/325159226_Resolution_of_chronic_rhinitis_to_staphylococcus_aureus_in_a_non-smoker_who_started_to_use_glycerine_based_e-cigarettes_Antibacterial_effects_of_vaping Resolution of chronic rhinitis to staphylococcus aureus in a non-smoker who started to use glycerine based e-cigarettes: Antibacterial effects of vaping?]=== | ||
===2017 [https://www.ncbi.nlm.nih.gov/pubmed/27940486 Moist smokeless tobacco (Snus) use and risk of Parkinson's disease]=== | |||
*Smoke-free nicotine appears to reduce the risk of Parkinson’s disease by 60%. | *Smoke-free nicotine appears to reduce the risk of Parkinson’s disease by 60%. | ||
*different website same study? [Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease|https://academic.oup.com/ije/article/46/3/872/2656164] | *different website same study? [Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease|https://academic.oup.com/ije/article/46/3/872/2656164] | ||
===2020 [https://n.neurology.org/content/neurology/94/20/e2132.full.pdf Tobacco smoking and the risk of Parkinson disease A 65-year follow-up of 30,000 male British doctors]=== | ===2020 [https://n.neurology.org/content/neurology/94/20/e2132.full.pdf Tobacco smoking and the risk of Parkinson disease A 65-year follow-up of 30,000 male British doctors]=== | ||
===[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]=== | ===[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]=== | ||
===Dr. Newhouse [http://mindstudy.org/news Mind Study]=== | ===Dr. Newhouse [http://mindstudy.org/news Mind Study]=== | ||
===[https://journals.sagepub.com/doi/abs/10.1177/0883073820974851?journalCode=jcna Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants]=== | ===[https://journals.sagepub.com/doi/abs/10.1177/0883073820974851?journalCode=jcna Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants]=== | ||
===2010 [https://pubmed.ncbi.nlm.nih.gov/20414766/ Meta-analysis of the acute effects of nicotine and smoking on human performance] and 2012 [https://n.neurology.org/content/78/2/91.short Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial]=== | ===2010 [https://pubmed.ncbi.nlm.nih.gov/20414766/ Meta-analysis of the acute effects of nicotine and smoking on human performance] and 2012 [https://n.neurology.org/content/78/2/91.short Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial]=== | ||
*Clinical studies suggest some cognitive improvements as a result of nicotine. | |||
===2021 [https://www.dovepress.com/effectiveness-and-safety-profile-of-alternative-tobacco-and-nicotine-p-peer-reviewed-fulltext-article-JMDH Effectiveness and Safety Profile of Alternative Tobacco and Nicotine Products for Smoking Reduction and Cessation: A Systematic Review]=== | |||
=== | ===[https://docs.google.com/document/d/13-D2q1P0KpmZuoFBkKV4l9wUEQ-zcHfp6MAVJGoAaG4/edit?usp=sharing INNCO's List smoking cessation]=== | ||
Started: continue @ “Among smokers who have attempted to stop without professional support, those who use e-cigarettes are more likely to report continued abstinence than those who used a licensed NRT products [i.e., nicotine patches, gum or lozenges].” | Started: continue @ “Among smokers who have attempted to stop without professional support, those who use e-cigarettes are more likely to report continued abstinence than those who used a licensed NRT products [i.e., nicotine patches, gum or lozenges].” | ||
https://onlinelibrary.wiley.com/doi/full/10.1111/add.12623 | https://onlinelibrary.wiley.com/doi/full/10.1111/add.12623 | ||
===[https://twitter.com/jkelovuori/status/1413963688709664769 Go through the links in this thread]=== | ===[https://twitter.com/jkelovuori/status/1413963688709664769 Go through the links in this thread]=== | ||
2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530045/ Caffeine intake and Cognitive Functions in Children] For comparison effects of caffeinated products | 2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530045/ Caffeine intake and Cognitive Functions in Children] For comparison effects of caffeinated products | ||
='''More Information'''= | ='''More Information'''= | ||
*[[Special:MyLanguage/Nicotine_Studies|'''List of researchers''']] studying nicotine / tobacco harm reduction | *[[Special:MyLanguage/Nicotine_Studies|'''List of researchers''']] studying nicotine / tobacco harm reduction | ||
*If you'd prefer someone else to add a study to a topic, there is a "topic" called "Suggested studies to add to this page". You may put the link in that section for one of the regular page editors to address. | *If you'd prefer someone else to add a study to a topic, there is a "topic" called "Suggested studies to add to this page". You may put the link in that section for one of the regular page editors to address. | ||
*'''PAGE EDITORS - Please only add Studies, Surveys, Papers in this format to keep page consistent for all viewers.''' | *'''PAGE EDITORS - Please only add Studies, Surveys, Papers in this format to keep page consistent for all viewers.''' | ||
**Topic | **Topic | ||
| Line 1,395: | Line 1,400: | ||
**Other | **Other | ||
[[Category:Studies, Surveys, and Papers]] | [[Category:Studies, Surveys, and Papers]] | ||
edits